SCHEMBL4602236

SCHEMBL4602236

CCC(F)C(F)(F)S(=O)(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14775259 0.80
SCHEMBL9169466 0.78
SCHEMBL7639800 0.76
SCHEMBL19857237 0.76 CA2 (0.39)
SCHEMBL216633 0.76 ALDH1A1 (0.32)
Lithium Ion SCHEMBL18007838 0.74
SCHEMBL18007980 0.74
Ammonia Solution, Strong SCHEMBL5470175 0.74 ALDH1A1 (0.31)
Potassium Ion SCHEMBL4455273 0.74
SCHEMBL12542079 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940803-A1 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS AstraZeneca AB (SE) 2008-07-09 EP disclosed
EP-1915364-A1 PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2008-04-30 EP disclosed
WO-2007031720-A1 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS ASTRAZENECA AB (SE) 2007-03-22 WO disclosed
WO-2007020388-A1 PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2007-02-22 WO disclosed